167 related articles for article (PubMed ID: 22146051)
21. Secreted aspartic proteases as virulence factors of Candida species.
Monod M; Borg-von ZM
Biol Chem; 2002; 383(7-8):1087-93. PubMed ID: 12437091
[TBL] [Abstract][Full Text] [Related]
22. Multiple effects of amprenavir against Candida albicans.
Braga-Silva LA; Mogami SS; Valle RS; Silva-Neto ID; Santos AL
FEMS Yeast Res; 2010 Mar; 10(2):221-4. PubMed ID: 20030734
[TBL] [Abstract][Full Text] [Related]
23. [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365].
Popov ME; Kashparov IV; Rumsh LD; Popov EM
Bioorg Khim; 1999 Jun; 25(6):418-22. PubMed ID: 10505229
[TBL] [Abstract][Full Text] [Related]
24. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
25. Two aspartic proteinases secreted by the pathogenic yeast Candida parapsilosis differ in expression pattern and catalytic properties.
Hrusková-Heidingsfeldová O; Dostál J; Majer F; Havlíkova J; Hradilek M; Pichová I
Biol Chem; 2009 Mar; 390(3):259-68. PubMed ID: 19166319
[TBL] [Abstract][Full Text] [Related]
26. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
Dunn BM; Pennington MW; Frase DC; Nash K
Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
[TBL] [Abstract][Full Text] [Related]
27. Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age.
Hoegl L; Korting HC; Klebe G
Pharmazie; 1999 May; 54(5):319-29. PubMed ID: 10368824
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs.
Flentge CA; Randolph JT; Huang PP; Klein LL; Marsh KC; Harlan JE; Kempf DJ
Bioorg Med Chem Lett; 2009 Sep; 19(18):5444-8. PubMed ID: 19679477
[TBL] [Abstract][Full Text] [Related]
29. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
30. Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants.
Frecer V; Miertus S; Tossi A; Romeo D
Drug Des Discov; 1998 Oct; 15(4):211-31. PubMed ID: 10546067
[TBL] [Abstract][Full Text] [Related]
31. Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases.
Blanco MT; Hurtado C; Pérez-Giraldo C; Morán FJ; González-Velasco C; Gómez-García AC
Med Mycol; 2003 Apr; 41(2):167-70. PubMed ID: 12964850
[TBL] [Abstract][Full Text] [Related]
32. Candida proteases and their inhibition: prospects for antifungal therapy.
Stewart K; Abad-Zapatero C
Curr Med Chem; 2001 Jul; 8(8):941-8. PubMed ID: 11375761
[TBL] [Abstract][Full Text] [Related]
33. Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide.
Rezacova P; Brynda J; Lescar J; Fabry M; Horejsi M; Sieglova I; Sedlacek J; Bentley GA
J Struct Biol; 2005 Mar; 149(3):332-7. PubMed ID: 15721587
[TBL] [Abstract][Full Text] [Related]
34. Domain flexibility in retroviral proteases: structural implications for drug resistant mutations.
Rose RB; Craik CS; Stroud RM
Biochemistry; 1998 Feb; 37(8):2607-21. PubMed ID: 9485411
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
[TBL] [Abstract][Full Text] [Related]
36. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
Kempf DJ; Sham HL; Marsh KC; Flentge CA; Betebenner D; Green BE; McDonald E; Vasavanonda S; Saldivar A; Wideburg NE; Kati WM; Ruiz L; Zhao C; Fino L; Patterson J; Molla A; Plattner JJ; Norbeck DW
J Med Chem; 1998 Feb; 41(4):602-17. PubMed ID: 9484509
[TBL] [Abstract][Full Text] [Related]
37. Cloning and characterization of Sapp2p, the second aspartic proteinase isoenzyme from Candida parapsilosis.
Merkerová M; Dostál J; Hradilek M; Pichová I; Hrusková-Heidingsfeldová O
FEMS Yeast Res; 2006 Nov; 6(7):1018-26. PubMed ID: 17042751
[TBL] [Abstract][Full Text] [Related]
38. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors.
Cutfield SM; Dodson EJ; Anderson BF; Moody PC; Marshall CJ; Sullivan PA; Cutfield JF
Structure; 1995 Nov; 3(11):1261-71. PubMed ID: 8591036
[TBL] [Abstract][Full Text] [Related]
39. The crystal structure of the secreted aspartic proteinase 3 from Candida albicans and its complex with pepstatin A.
Borelli C; Ruge E; Schaller M; Monod M; Korting HC; Huber R; Maskos K
Proteins; 2007 Aug; 68(3):738-48. PubMed ID: 17510964
[TBL] [Abstract][Full Text] [Related]
40. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
